X
AZ talks up Bydureon data, GLP-1 and glucagon combo
https://pharmaphorum.com/news/az-hopes-bydureon-mortality-benefit-stave-off-threat-novo/
Type 2 diabetes
More data supports Jardiance lead in cardiovascular battle
Cardioprotective effect occurred in patients independently of blood sugar control
Novo’s semaglutide outperforms Lilly GLP-1 rival
If approved semaglutide could become set the standard for GLP-1 therapy
The Berlin Declaration – driving early action in type 2 diabetes
International initiative helps countries focus on best policies for overcoming diabetes.
1 2